| Literature DB >> 33247694 |
Maha Elsayed Mohammed Salama1.
Abstract
BACKGROUND: Lung cancer, being the leading cause of cancer deaths with most patients diagnosed at a late stage, represents a major burden in developing countries especially with both air pollution and tobacco use increasing. With the evolution of new, successful therapies that target lung adenocarcinoma, it became of utmost importance to diagnose lung adenocarcinoma. Despite considering TTF-1 as the predominant marker for identifying lung adenocarcinoma but it has limited sensitivity and specificity, which means that its expression decreases in relation to the degree of tumor differentiation. AIM OF WORK: this study intended to evaluate the use of Napsin A in lung adenocarcinoma, and observe if it can withstand along the different lines of tumor differentiation and Survivin as a marker of poor prognosis.Entities:
Keywords: Lung; Nap A; cancer
Mesh:
Substances:
Year: 2020 PMID: 33247694 PMCID: PMC8033138 DOI: 10.31557/APJCP.2020.21.11.3345
Source DB: PubMed Journal: Asian Pac J Cancer Prev ISSN: 1513-7368
Figure 1A Case of Bronchogenic Adenocarcinoma Grade I Showing Strong Napsin A Immunoexpression (Napsin A x200 Original Power).
Figure 2A Case of Bronchogenic Adenocarcinoma Grade III Showing Negative Napsin A Immunoexpression (Napsin A x400 Original Power)
Figure 3A Case of Bronchogenic Adenocarcinoma Grade II Showing Survivin Immunoexpression Labeling Index <10% (Survivin x200 Original Power)
Figure 4A Case of Bronchogenic Adenocarcinoma Grade III Showing Survivin Immunoexpression Labeling Index >10% (Survivin x200 Original Power)
Relation between Napsin A Staining Intensity and Survivin Labeling Index (LI)
| Number of cases | Napsin A | Survivin | P value | |
|---|---|---|---|---|
| <10% LI | >10% LI | |||
| 10 | Negative | 0 | 100% | <0.05 |
| 7 | Weak | 100% | 0 | |
| 23 | Strong | 100% | 0 | |
| Total 40 cases | ||||